Statins are the most prescribed drug class in the United States. Approximately 40 million Americans take them daily. They are presented as one of modern medicine’s clearest success stories — a safe, effective intervention that saves lives by lowering cholesterol and preventing heart attacks. The prescribing guidelines that drive this level of use were written by committees with documented financial ties to the manufacturers of these drugs. The clinical trial data that supports them has been selectively published. The side effects are underreported in both trials and clinical practice. And the fundamental premise — that cholesterol is a primary driver of heart disease and that lowering it with a drug prevents death — is more contested in the peer-reviewed literature than the official line suggests.
This post is not an argument that heart disease is not serious or that no one benefits from statins. Some people do, particularly men who have already had a heart attack. It is an argument that the conversation most patients have at the point of prescribing is missing critical information that should be part of informed consent — and that you deserve to have that information before you decide.
Important: If you are currently taking statins, do not stop abruptly based on anything in this post. The dependency statins create is real and stopping without medical guidance carries its own risks. This post is about informed decision-making, not a directive to discontinue medication.
WHAT CHOLESTEROL ACTUALLY IS AND WHAT YOUR BODY USES IT FOR
Before the drug, understand the molecule. Cholesterol is not a dietary mistake or a metabolic accident. It is one of the most essential compounds in the human body — so essential that your liver manufactures most of it regardless of what you eat, because the body cannot risk being without it.
The brain is approximately 2% of body weight but contains roughly 25% of the body total cholesterol. Every neuron is wrapped in a myelin sheath — the insulating layer that allows nerve signals to travel at speed. Myelin is made primarily from cholesterol. Without adequate cholesterol, nerve conduction slows and degrades. This is not theoretical — it is why cognitive symptoms including memory impairment, confusion, and what patients describe as brain fog are among the most commonly reported statin side effects. Studies consistently show that elderly people with higher cholesterol levels outlive those with low cholesterol. The brain simply requires it to function.
Beyond the brain: every cell membrane in the human body contains cholesterol. It provides structural integrity and controls what passes in and out of cells. The liver uses cholesterol to produce bile acids essential for fat digestion. The skin uses cholesterol as a precursor to vitamin D when exposed to sunlight. And critically — the adrenal glands, ovaries, and testes use cholesterol as the direct precursor to every steroid hormone in the body. Cortisol, estrogen, progesterone, testosterone, DHEA — all synthesized from cholesterol. Suppressing cholesterol production suppresses the raw material for the entire hormonal system. This is why statin users commonly report hormonal disruption, reduced libido, fatigue, and mood changes that their doctors rarely connect to the drug.
HOW THE THRESHOLD GOT MOVED
For most of the 20th century, total cholesterol above 240 mg/dL was considered elevated and potentially worth treating. In 2004, the National Cholesterol Education Program updated its guidelines, lowering the recommended LDL target from 130 mg/dL to 100 mg/dL for high-risk patients, and adding an optional target of 70 mg/dL for very high-risk patients. The effect was immediate and enormous: tens of millions of Americans who had previously been in the normal category were reclassified as needing treatment overnight — not because their health had changed, but because the number had changed.
Eight of the nine panel members who wrote those 2004 guidelines had financial ties to statin manufacturers. This was disclosed — in small print — after the guidelines were published and after the resulting prescription surge had begun.
The same pattern continued with the 2013 ACC/AHA guidelines, which abandoned specific LDL targets entirely and instead recommended statins for broad population categories based on a cardiovascular risk calculator — a calculator that independent researchers found significantly overestimated risk, potentially by a factor of two. That would mean millions of people were recommended statins based on a risk assessment that overstated their actual risk by 100%.
ABSOLUTE RISK VS. RELATIVE RISK — THE NUMBER THEY TELL YOU AND THE ONE THEY DO NOT
This is the most important statistical sleight of hand in the statin conversation and it happens in almost every prescribing discussion.
When a doctor says statins reduce heart attack risk by 36%, that is a relative risk reduction. It sounds dramatic. Here is what it means in absolute terms using actual trial data: in the JUPITER trial — one of the most cited statin trials — the absolute risk of a cardiovascular event in the placebo group over 1.9 years was 1.8%. In the statin group it was 0.9%. The relative risk reduction is 50%. The absolute risk reduction is 0.9 percentage points. To prevent one cardiovascular event, approximately 120 people needed to take statins for two years. The other 119 received no benefit but were exposed to the drug side effects for the full period.
This is what Number Needed to Treat (NNT) means — how many people must take a drug for one person to benefit. For statins used in primary prevention (people who have never had a heart attack), the NNT ranges from approximately 50 to 200 depending on the trial and population. For secondary prevention (people who have already had a heart attack), the NNT is significantly lower — statins have clearer benefit in this population. The majority of statin prescriptions in the United States are for primary prevention. The majority of patients receiving them will derive no measurable benefit while being exposed to real side effect risk.
Patients are told the relative risk number. Almost none are told the absolute risk number or the NNT. Informed consent requires both.
WHAT STATINS ACTUALLY DO — THE FULL MECHANISM
Statins work by inhibiting HMG-CoA reductase — the enzyme your liver uses to synthesize cholesterol. The same HMG-CoA reductase pathway that produces cholesterol also produces Coenzyme Q10 (CoQ10) — a compound essential for mitochondrial energy production in every cell in the body, and particularly critical in muscle cells including heart muscle. Statins block CoQ10 production along with cholesterol.
This is why muscle pain and weakness (myopathy) are among the most common statin side effects — muscle cells are being starved of the energy compound they need to function. In severe cases this progresses to rhabdomyolysis, the breakdown of muscle tissue, which can cause acute kidney failure. The FDA added a warning about cognitive side effects and type 2 diabetes risk to statin labels in 2012 — these are not rare reactions but documented consequences of the drug mechanism.
The statin-CoQ10 depletion link was known to the pharmaceutical industry early. Merck filed patents in 1989 for statin formulations combined with CoQ10 to address this problem — patents they never commercialized. The drug is sold without the CoQ10 that would mitigate its own side effect. Many physicians who do prescribe statins recommend CoQ10 supplementation alongside them, though this is not standard practice and is rarely mentioned at the point of prescribing.
THE DEPENDENCY — WHAT LONG-TERM USE CREATES
With the HMG-CoA reductase pathway chronically suppressed by the drug, the body progressively downregulates its own endogenous cholesterol synthesis capacity. The liver adapts to the drug doing the work. After months to years of use, the body ability to produce adequate cholesterol independently is compromised.
This creates a dependency that is almost never disclosed at the point of prescribing. When patients attempt to stop statins — whether by choice, due to side effects, due to cost, or on a physician recommendation — the suppressed endogenous pathway does not immediately recover. There is a rebound period where cholesterol synthesis is inadequate. In some patients this window has been associated with increased cardiovascular risk. The pharmaceutical industry uses this rebound risk as evidence that statins must be continued indefinitely — which is a convenient argument when the drug itself created the dependency that makes stopping risky.
Patients who want to discontinue statins should do so gradually and with medical supervision. Most prescribing physicians do not discuss this because most do not anticipate the patient ever stopping the drug. It is designed as a lifetime prescription.
THE SUPPRESSED DATA
Most major statin trials were funded by the manufacturers of the drugs being tested. What is documented in the statin literature is a pattern of selective publication: trials with positive results were published; trials with negative or neutral results were not. A 2010 analysis found that industry-funded statin trials were significantly more likely to report positive results than independently funded trials of the same drugs.
The raw data from the major statin trials — held by the Cholesterol Treatment Trialists Collaboration — has never been made available to independent researchers for analysis. The evidence base for the most prescribed drug class in the world rests on analyses performed by groups with financial relationships to the manufacturers, from data that has not been independently verified.
Dr. John Abramson at Harvard Medical School and other independent researchers who have analyzed the available published data have consistently found the absolute benefits of statins in primary prevention to be much smaller than the marketed claims, and the harms — particularly muscle damage, diabetes risk, and cognitive effects — to be more significant than the official safety profile acknowledges.
WHAT ACTUALLY DRIVES CARDIOVASCULAR DISEASE
The lipid hypothesis — that dietary saturated fat raises LDL cholesterol and LDL cholesterol causes heart disease — has been significantly revised in the research over the last two decades, though the prescribing guidelines have not kept up. It is not total LDL that predicts cardiovascular risk most accurately but oxidized LDL — LDL particles that have been damaged by oxidative stress. Small, dense LDL particles are more dangerous than large, buoyant ones. Inflammation — measured by markers like C-reactive protein — is a stronger predictor of cardiovascular events in many studies than LDL level.
Factors with strong evidence for cardiovascular risk that do not involve cholesterol: smoking, insulin resistance and metabolic syndrome, chronic inflammation, hypertension, sedentary lifestyle, sleep deprivation, chronic psychological stress, seed oil consumption and its oxidation products, and visceral adiposity. Addressing these through diet, movement, sleep, and stress management has documented cardiovascular benefit that pharmaceutical cholesterol lowering does not replicate.
SUPPORTING YOUR BODY
CoQ10: Whether you are currently taking statins or have taken them in the past, CoQ10 repletion is relevant. Ubiquinol form is better absorbed than ubiquinone, particularly in people over 40. Dietary sources include organ meats, sardines, mackerel, beef, and peanuts.
Endogenous cholesterol pathway support: The liver cholesterol synthesis depends on adequate B vitamins (particularly B12, folate, and B6), magnesium, zinc, and vitamin C. Supporting these nutritionally supports the pathway recovery capacity for anyone tapering off statins.
Berberine: A plant alkaloid found in goldenseal, barberry, and Oregon grape with documented LDL-lowering effects through a different mechanism than statins. Multiple studies have found berberine reduces LDL comparably to low-dose statins without the HMG-CoA reductase suppression and without the CoQ10 depletion. It also improves insulin sensitivity, which addresses one of the actual drivers of cardiovascular risk.
Anti-inflammatory diet: Addressing oxidized LDL and systemic inflammation through diet is more mechanistically targeted than simply lowering total LDL. Extra virgin olive oil, fatty fish, walnuts, flaxseed, turmeric, ginger, dark leafy greens, and elimination of seed oils and ultra-processed food address the oxidative and inflammatory pathways that damage arterial walls.
Cross-reference: Know Your Medication — Building Your Protocol | Know Your Food — Seed Oils | Know Your Body | Herbal Remedies | Root Cellar
FROM THE BUNKER
White Coats in the Smoke — Civic Hush
“Who made the cure they did / Who owns the gate they hid / Who keeps the score the board / Who takes the blame ignored.”
Civic Hush wrote the conflict of interest section of this post before this post existed. The trial data no one can access, the guidelines written by the people who profit from them, the score kept by the board.
Listen on KaNafia
FROM THE WASTELAND
Leaf Juice — Wasteland Survival Series, Book 1
Berberine-containing herbs including goldenseal and barberry, and the anti-inflammatory and liver support preparations relevant to cholesterol metabolism, have preparation protocols in Leaf Juice.
Paperback | Kindle